Foundayo (Orforglipron): Better Than Mounjaro & Wegovy? | Pharmacist Explains

Will the new once-daily Orforglipron pill disrupt the GLP-1 weight loss market? What we are covering: The chemistry behind it and how it works What the trial data actually tells us How this stacks up against the injectable heavyweights like Mounjaro, Wegovy and Zepbound and the new semaglutide pill What this all means for your health and your wallet About the host - I’m Dave, a licensed Pharmacist in Great Britain with over 25 years of clinical experience. This analysis focuses on clinical trial data, licensing status, and the self-funded private market landscape for GLP-1 weight loss therapy. Indications, NHS availability, insurance coverage, and individual eligibility vary significantly by region. Always consult your prescribing clinician regarding your specific access pathway. To keep the narrative tight and focused on weight management, this breakdown highlights GLP-1 mechanisms related to fullness and gastric emptying. Orforglipron also retains classic incretin pathways, including glucose-dependent insulin secretion and glucagon suppression. 00:00 - Introduction and eligibility 01:47 - How does Orforglipron work? 02:15 - The problem with synthetic Peptides 03:18 - What are Peptides? 03:33 - How to get an oral GLP-1 agonist to work 04:12 - The difference between Orforglipron and Mounjaro/Zepbound (tirzepatide) 04:48 - Mounjaro/Zepbound (tirzepatide) weight loss data 05:05 - Orforglipron weight loss data 06:20 - Capsule vs. Tablet bioequivalence 07:00 - Benefits beyond weight loss 07:18 - Warnings and side effects 09:20 - Drug Interactions 10:32 - Who is this pill for exactly? 12:22 - Pricing and cost breakdown 13:05 - Full comparison: Orforglipron vs. Mounjaro/Zepbound (tirzepatide), Wegovy injection and Wegovy pill (semaglutide) 13:50 - Key takeaways 14:37 - Final thoughts and oral semaglutide video recommendation Check out my oral semaglutide video here:    • Wegovy (Semaglutide) tablet for weight los...   Business Enquiries: partnershipsadoseofdave@gmail.com RESOURCES AND SCIENTIFIC REFERENCES: ATTAIN-1 - https://www.nejm.org/doi/10.1056/NEJM... ATTAIN-MAINTAIN - https://www.nature.com/articles/s4159... OASIS-4 - https://www.nejm.org/doi/abs/10.1056/... SURMONT-1 - https://www.nejm.org/doi/pdf/10.1056/... STEP -1 - https://www.nejm.org/doi/pdf/10.1056/... Pharmacokinetic Bioequivalence of Orforglipron Tablets and Capsules in Healthy Participants With Obesity or Overweight - https://pubmed.ncbi.nlm.nih.gov/41994... FDA Orforglipron Prescribing Information - https://www.accessdata.fda.gov/drugsa... DISCLAIMER A Dose of Dave is strictly for entertainment, general medical education, and public information purposes only. Interacting with this channel does not establish a pharmacist-patient relationship between you and Dave. Nothing here constitutes personal medical advice, clinical diagnosis, or treatment recommendations. Always consult your own qualified healthcare provider before starting, stopping, or altering any medication or treatment. © A Dose of Dave. All rights reserved. Permission is denied to clip, isolate, or redistribute this content. Dave accepts no liability for unauthorised edits. #Foundayo #Orforglipron #GLP1 #WeightLossPill #Mounjaro #Wegovy #PharmacistExplains